Patents by Inventor So Jung LIM

So Jung LIM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240225987
    Abstract: Provided a liquid crystal composition including ceramide, a method of preparing the same, and a cosmetic composition including the same. According to a liquid crystal composition including various types of ceramide of an aspect and a method of preparing the same, the liquid crystal composition not only has high liquid crystal stability that liquid crystal is maintained even after 4 weeks at a high temperature, but also activities of increasing an amount of ceramide, increasing an expression level of aquaporin 3, increasing an amount of filaggrin, increasing an expression level of hyaluronic acid, increasing an expression level of loricrin, increasing an expression level of involucrin, and increasing a thickness of the skin, resulting in effects usefully available for amelioration of the skin conditions.
    Type: Application
    Filed: April 4, 2023
    Publication date: July 11, 2024
    Applicant: Croda Korea Ltd
    Inventors: Ji Hye HAN, Sang Chul KIM, Mi Kyung SUNG, So Jung LIM, Seung Won PARK
  • Publication number: 20240173240
    Abstract: Provided is a cosmetic composition including ceramides and a sphingolipid. A composition including two or more different ceramides and a sphingolipid, according to an embodiment, has the activity of increasing a ceramide content in the skin, increasing the expression level of aquaporin 3, increasing the expression level of fillaggrin, increasing the expression level of loricrin, increasing the expression level of involucrin, and increasing the skin thickness, and thus can be effectively used for improving skin conditions.
    Type: Application
    Filed: April 4, 2023
    Publication date: May 30, 2024
    Applicant: Croda Korea Ltd
    Inventors: So Jung LIM, Mi Kyung SUNG, Sang Chul KIM, Ji Hye HAN, Seung Won PARK
  • Publication number: 20240130950
    Abstract: Provided a liquid crystal composition including ceramide, a method of preparing the same, and a cosmetic composition including the same. According to a liquid crystal composition including various types of ceramide of an aspect and a method of preparing the same, the liquid crystal composition not only has high liquid crystal stability that liquid crystal is maintained even after 4 weeks at a high temperature, but also activities of increasing an amount of ceramide, increasing an expression level of aquaporin 3, increasing an amount of filaggrin, increasing an expression level of hyaluronic acid, increasing an expression level of loricrin, increasing an expression level of involucrin, and increasing a thickness of the skin, resulting in effects usefully available for amelioration of the skin conditions.
    Type: Application
    Filed: April 3, 2023
    Publication date: April 25, 2024
    Applicant: Croda Korea Ltd
    Inventors: Ji Hye HAN, Sang Chul KIM, Mi Kyung SUNG, So Jung LIM, Seung Won PARK
  • Publication number: 20220162310
    Abstract: The present invention relates to: an antibody to T cell Immunoreceptor with Ig and Tyrosine-Based Inhibitory Motif Domains (TIGIT), or an antigen-binding fragment thereof; a nucleic acid encoding same; a vector carrying the nucleic acid; a cell transformed with the vector; a method for producing the antibody or the antigen-binding fragment thereof; and a composition and a composition for combined administration, which comprise same and are for preventing or treating cancer.
    Type: Application
    Filed: May 22, 2020
    Publication date: May 26, 2022
    Inventors: Hye-Young PARK, Eun Jung SONG, Eun Hee LEE, Hye In YUM, Hye Mi NAM, Mun Kyung KIM, Jee Won LEE, Joong Hyuk SHEEN, Min Kyu HUR, So Jung LIM, Ok Jae LIM, Yang Mi LIM, Jong Hwa WON
  • Publication number: 20220135679
    Abstract: A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.
    Type: Application
    Filed: April 6, 2020
    Publication date: May 5, 2022
    Applicant: GREEN CROSS CORPORATION
    Inventors: Jae Chan PARK, Eun Jung SONG, So Jung LIM, Jae-Chul LEE, Hae Naem KWON, Su A LEE, Ok Jae LIM, Mun Kyung KIM, Hyun Jung CHO, Gil-Jung KIM, Jee Won LEE, Sung Keun KIM, Jong Wha WON, Shin A JANG